Canagliflozin
- Generic Name
- Canagliflozin
- Brand Names
- Invokamet, Invokana
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25FO5S
- CAS Number
- 842133-18-0
- Unique Ingredient Identifier
- 6S49DGR869
- Background
Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise .
...
- Indication
This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus .
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Major Adverse Cardiac Events, Type 2 Diabetes Mellitus, Doubling of serum creatinine
- Associated Therapies
- -
Pharmacogenetics of SGLT2 Inhibitors
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 30
- Registration Number
- NCT02462421
Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 67
- Registration Number
- NCT02404870
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Mechanisms of Weight Loss With SGLT2 Inhibition
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-02-11
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT02360774
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 138
- Registration Number
- NCT02354235
- Locations
- 🇯🇵
Reserch site, Tohoku, Japan
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 154
- Registration Number
- NCT02354222
- Locations
- 🇯🇵
Reserch site, Tohoku, Japan
Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2019-12-18
- Target Recruit Count
- 45
- Registration Number
- NCT02324842
- Locations
- 🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 335
- Registration Number
- NCT02243202
Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 2
- Registration Number
- NCT02221180
Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 2
- Registration Number
- NCT02220218
Glycemic Durability After Metformin Failure
Phase 4
- Conditions
- Interventions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 450
- Registration Number
- NCT02142309
- Locations
- 🇮🇹
Department of Geriatrics and Metabolic Diseases, Naples, Italy
🇮🇹Katherine Esposito, Naples, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath